Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study for Patients With Advanced Triple Negative or Metaplastic HR-positive/HER2-negative, PIK3CA/PTEN-altered Breast Cancer Treated With Eribulin in Combination With MEN1611

Next Previous
Trial Profile

Phase II Study for Patients With Advanced Triple Negative or Metaplastic HR-positive/HER2-negative, PIK3CA/PTEN-altered Breast Cancer Treated With Eribulin in Combination With MEN1611

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEN 1611 (Primary) ; Eribulin
  • Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer
  • Focus First in man; Therapeutic Use
  • Acronyms SABINA

Most Recent Events

  • 10 Mar 2026 Status changed from recruiting to active, no longer recruiting.
  • 22 Sep 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Apr 2026.
  • 20 Dec 2024 Planned number of patients changed from 28 to 14.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top